Addressing Myths and Misconceptions about MDMA Assisted Therapy (Part 2)

As MDMA-assisted therapy moved toward regulatory approval in 2024, misinformation and oversimplifications shaped public, professional, and regulatory discourse on the topic. Today, misunderstandings about the form of MDMA-assisted therapy provided in the Phase 3 trials persist. This panel brings together leading clinician-researchers to address key myths and misconceptions about the content, process, and safety of this treatment. Deepening and expanding upon the discussion begun in Part 1 (6/18, Therapy Stage), this panel will highlight the key distinctions, corrections, and clarifications required for a more accurate and meaningful appraisal of the efficacy and safety of MDMA-assisted therapy.